https://www.scribetx.com https://www.scribetx.com/about https://www.scribetx.com/careers https://www.scribetx.com/news https://www.scribetx.com/privacy https://www.scribetx.com/contact https://www.scribetx.com/platform https://www.scribetx.com/pipeline https://www.scribetx.com/news/2020-was-the-turning-point-for-crispr https://www.scribetx.com/news/2025-predictions-which-trends-are-set-to-shape-the-biotech-industry-this-year https://www.scribetx.com/news/40-under-40-benjamin-oakes-scribe-therapeutics https://www.scribetx.com/news/5-novel-therapies-using-synthetic-biology https://www.scribetx.com/news/8-biocom-member-companies-leveraging-crispr-technology https://www.scribetx.com/news/a-crispr-collaboration-compilation https://www.scribetx.com/news/a-decade-later-biotechs-crispr-revolution-is-still-going-strong https://www.scribetx.com/news/a-new-approach-to-crispr---scribe-therapeutics-designs-novel-crispr-molecules https://www.scribetx.com/news/a-road-to-survival https://www.scribetx.com/news/advancing-crispr-cures-requires-cross-sector-collaboration https://www.scribetx.com/news/appointments-and-advancements https://www.scribetx.com/news/benjamin-oakes-and-the-promise-of-crispr https://www.scribetx.com/news/big-money-for-gene-editing-engineering-structure-based-drug-design-and-data-management https://www.scribetx.com/news/big-pharma-is-waking-up-to-the-booming-field-of-gene-editing-here-are-the-top-18-biotechs-to-know-in-2022-that-are-poised-to-grab-the-drug-industrys-attention https://www.scribetx.com/news/biocom-catalyst-awards https://www.scribetx.com/news/biogen-gene-editing-startup-scribe-to-develop-therapies-for-lou-gehrigs-disease https://www.scribetx.com/news/biogen-pursues-another-neuro-target-with-scribe https://www.scribetx.com/news/biogen-scribe-to-develop-additional-gene-therapy-disease-target https://www.scribetx.com/news/biogen-takes-another-dip-into-scribe-gene-therapy-collab-with-another-disease-target https://www.scribetx.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme https://www.scribetx.com/news/biospace-40-under-40 https://www.scribetx.com/news/biospace-movers-shakers https://www.scribetx.com/news/biotech-scribe-strikes-gene-editing-deal-with-lilly-subsidiary https://www.scribetx.com/news/building-a-biotech-in-a-downturn-3-lessons-from-vcs-and-startup-ceos https://www.scribetx.com/news/c-ens-year-in-pharma-2019 https://www.scribetx.com/news/california-life-sciences-announces-2021-pantheon-award-winners https://www.scribetx.com/news/can-ai-take-the-guesswork-out-of-crispr https://www.scribetx.com/news/can-genetic-medicine-solve-cardiovascular-disease https://www.scribetx.com/news/casx-start-up-scribe-therapeutics-raises-100-million-for-crispr-therapies https://www.scribetx.com/news/ceo-of-doudna-spinout-within-five-years-genome-editors-will-have-a-really-big-impact-on-patients-lives https://www.scribetx.com/news/cfos-on-the-move https://www.scribetx.com/news/chutes-ladders https://www.scribetx.com/news/crispr-2-0-the-next-generation https://www.scribetx.com/news/crispr-based-als-treatment-being-developed-by-scribe-and-biogen https://www.scribetx.com/news/crispr-by-design-with-benjamin-oakes https://www.scribetx.com/news/crispr-casx-could-be-the-next-small-gene-editing-enzyme https://www.scribetx.com/news/crispr-drug-licensing-deals-secure-21bn-in-top-three-therapy-areas-over-five-years https://www.scribetx.com/news/crispr-enzyme-from-groundwater-bacteria-shows-unusual-properties https://www.scribetx.com/news/crispr-partnerships-propel-precision-medicine https://www.scribetx.com/news/crispr-pioneers-biotech-taps-ex-barclays-banker-as-cfo https://www.scribetx.com/news/crispr-slashes-bad-cholesterol-levels-by-95-percent-in-early-results https://www.scribetx.com/news/crispr-startup-scribe-therapeutics-lands-big-biogen-deal https://www.scribetx.com/news/crispr-technologies-fuelling-haematological-innovations https://www.scribetx.com/news/crispr-technologys-next-wave-eight-companies-to-watch-in-2024 https://www.scribetx.com/news/crisprmed25-virtual-event-roundup https://www.scribetx.com/news/crisprs-cardio-catch-all-drives-a-biotechs-broad-potential https://www.scribetx.com/news/deals-in-depth-september-2022 https://www.scribetx.com/news/dna-cutting-the-future-of-genome-editing https://www.scribetx.com/news/dna-island-alameda-is-attracting-biotechs-amid-an-industrywide-downturn https://www.scribetx.com/news/doudna-inc-how-cal-scientist-created-a-biotech-startup-engine https://www.scribetx.com/news/doudna-spin-out-scribe-partners-with-biogen-on-crispr-based-treatment-for-als https://www.scribetx.com/news/doudnas-scribe-rewrites-crispr-drug-development-with-100-million-series-b https://www.scribetx.com/news/doudnas-scribe-unveils https://www.scribetx.com/news/east-bays-scribe-therapeutics-lands-2nd-big-deal-with-sanofi-this-one-aimed-initially-at-sickle-cell-disease https://www.scribetx.com/news/economic-forecast-2023 https://www.scribetx.com/news/engineering-crispr-with-ben-oakes https://www.scribetx.com/news/engineering-the-future-of-genetic-medicine https://www.scribetx.com/news/engineering-the-future-of-genetic-medicine-180b3 https://www.scribetx.com/news/engineering-the-future-of-genetic-medicine-64241 https://www.scribetx.com/news/epigenetic-approach-shows-durable-pcsk9-silencing-in-primates https://www.scribetx.com/news/epigenetic-editors-are-a-gentler-form-of-gene-editing https://www.scribetx.com/news/exciting-new-crispr-casx-variant-could-be-swiss-army-knife-for-genetics https://www.scribetx.com/news/fda-approves-crispr-cas9-therapy-for-sickle-cell-disease https://www.scribetx.com/news/follow-the-money https://www.scribetx.com/news/from-the-lab-to-the-clinic-developing-and-delivering-the-next-generation-of-therapies-to-patients-in-need https://www.scribetx.com/news/from-tools-to-trials-editing-therapy-companies-pivot-to-development https://www.scribetx.com/news/future-of-epigenetic-medicine https://www.scribetx.com/news/future-of-genetic-medicine-w-scribe-therapeutics-founders https://www.scribetx.com/news/getting-to-the-heart-of-crispr-based-therapies https://www.scribetx.com/news/growing-east-bay-biotech-scribe-therapeutics-lines-up-potential-1-5-billion-crispr-deal https://www.scribetx.com/news/heart-disease-could-be-a-goner-when-these-new-drugs-arrive https://www.scribetx.com/news/how-jennifer-doudnas-life-has-changed-since-discovering-crispr-10-years-ago https://www.scribetx.com/news/industry-appetite-for-natural-killer-cells-intensifies https://www.scribetx.com/news/influential-women-2023-svetlana-lucas-chief-business-officer-scribe-therapeutics https://www.scribetx.com/news/innovators-under-35-2022 https://www.scribetx.com/news/interview-with-scribe-therapeutics-ceo-benjamin-oakes https://www.scribetx.com/news/jennifer-doudnas-new-gene-editing-company-launches-with-a-20-million-round-to-develop-genetic-medicines https://www.scribetx.com/news/jennifer-doudnas-scribe-therapeutics-lands-a-100m-series-b-to-advance-crispr-technology https://www.scribetx.com/news/leadership-essentials-inspire-motivate-and-cultivate https://www.scribetx.com/news/lilly-scribe-team-up-for-neuro-diseases-crispr-therapies-in-75m-upfront-cash-equity-deal https://www.scribetx.com/news/lilly-subsidiary-scribe-ink-up-to--1-5b-crispr-based-neuro-collaboration https://www.scribetx.com/news/lillys-prevail-doudnas-scribe-partner-on-genetic-treatments-for-neuro-diseases https://www.scribetx.com/news/management-tracks https://www.scribetx.com/news/medtech-breakthrough-awards-2021-winners https://www.scribetx.com/news/meet-the-12-biotechs-pioneering-cutting-edge-cures-that-stand-to-upend-how-we-treat-diseases-and-transform-pharma https://www.scribetx.com/news/meet-the-30-young-leaders-forging-a-new-future-for-the-healthcare-industry-in-2021 https://www.scribetx.com/news/natural-killers-gain-more-attention-with-major-franco-us-collab https://www.scribetx.com/news/new-protein-could-deliver-next-gene-editing-tool https://www.scribetx.com/news/novel-gene-editing-systems-come-into-their-own https://www.scribetx.com/news/peer-review https://www.scribetx.com/news/peer-review-dd1a8 https://www.scribetx.com/news/sanofi-and-jennifer-doudna-founded-scribe-ink-1b-crispr-cell-therapy-deal https://www.scribetx.com/news/sanofi-and-scribes-expanded-deal-builds-path-to-in-vivo-editing-in-scd https://www.scribetx.com/news/sanofi-doudna-founded-scribe-therapeutics-to-target-sickle-cell-disease-in-new-pact https://www.scribetx.com/news/sanofi-expands-collaboration-with-scribe-on-crispr-genome-editing https://www.scribetx.com/news/sanofi-expands-research-deal-with-gene-editing-startup-scribe https://www.scribetx.com/news/sanofi-goes-back-to-scribe https://www.scribetx.com/news/sanofi-licenses-crispr-enzyme-in-bid-to-develop-safer-simpler-sickle-cell-cure https://www.scribetx.com/news/sanofi-partners-with-scribe-to-gain-gene-editing-tools-for-cell-therapy-work https://www.scribetx.com/news/sanofi-pays-scribe-25m-to-access-crispr-tools-writing-new-chapter-in-its-nk-cell-therapy-story https://www.scribetx.com/news/sanofi-scribe-launch-up-to--1b-crispr-based-cancer-nk-cell-therapy-collaboration https://www.scribetx.com/news/sanofi-taps-scribe-for-in-vivo-partnership-worth-more-than-1-2b-biobucks-aimed-at-sickle-cell-and-beyond https://www.scribetx.com/news/sanofi-thinks-scribes-crispr-approach-can-advance-its-nk-cell-therapy-goals https://www.scribetx.com/news/sanofi-to-utilise-scribes-crispr-platform-to-develop-cancer-cell-therapies https://www.scribetx.com/news/sanofi-turns-to-a-jennifer-doudna-gene-editing-upstart-for-next-gen-nk-cell-alliance https://www.scribetx.com/news/sanofi-turns-to-startup-scribe-to-crispr-edit-new-nk-cell-therapies-for-cancer https://www.scribetx.com/news/sanofis-nk-cell-toolbox-grows-with-scribes-next-gen-editor https://www.scribetx.com/news/scribe-achieves-milestone-for-in-vivo-program-in-collaboration-with-prevail-therapeutics-a-part-of-lillys-gene-therapy-division-and-announces-asgct-joint-presentation-on-self-inactivating-aav-technology-for-neurological-and-neuromuscular-disorders https://www.scribetx.com/news/scribe-and-prevail-partner-for-crispr-based-genetic-medicines https://www.scribetx.com/news/scribe-and-prevail-to-accelerate-crispr-based-genetic-medicines-for-neurological-and-neuromuscular-diseases https://www.scribetx.com/news/scribe-and-sanofi-partner-to-develop-cell-therapies-for-cancer https://www.scribetx.com/news/scribe-announces-collaboration-with-prevail-a-wholly-owned-subsidiary-of-lilly-to-accelerate-in-vivo-crispr-based-genetic-medicines-for-neurological-and-neuromuscular-diseases https://www.scribetx.com/news/scribe-biogen-expand-als-crispr-agreement https://www.scribetx.com/news/scribe-biogen-partner-to-develop-gene-therapy-for-als-other-neurological-diseases https://www.scribetx.com/news/scribe-closes-100m-series-b-round-for-gene-editing-rewrite https://www.scribetx.com/news/scribe-engineering-crisprs-next-generation https://www.scribetx.com/news/scribe-eyes-clinic-after-crispr-candidates-lower-lipids-in-animals https://www.scribetx.com/news/scribe-inks-crispr-gene-editing-deal-with-prevail https://www.scribetx.com/news/scribe-jennifer-doudnas-newest-startup-nabs-a-mega-round-and-a-vocal-investor https://www.scribetx.com/news/scribe-pens-1-5b-plus-crispr-tech-deal-with-lilly https://www.scribetx.com/news/scribe-pursues-crispr-therapies-with-expanded-biogen-collaboration https://www.scribetx.com/news/scribe-signs-another-big-pharma-deal https://www.scribetx.com/news/scribe-therapeutics-achieves-milestone-for-in-vivo-program-in-collaboration-with-sanofi https://www.scribetx.com/news/scribe-therapeutics-achieves-second-success-milestone-for-in-vivo-program-in-collaboration-with-eli-lilly-and-company https://www.scribetx.com/news/scribe-therapeutics-and-sanofi-collaborate-on-in-vivo-therapies-for-sickle-cell-disease https://www.scribetx.com/news/scribe-therapeutics-announces-expansion-of-san-francisco-bay-area-headquarters-3-key-senior-hires https://www.scribetx.com/news/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting https://www.scribetx.com/news/scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer https://www.scribetx.com/news/scribe-therapeutics-appoints-david-parrot-as-chief-financial-officer-and-george-manning-as-controller https://www.scribetx.com/news/scribe-therapeutics-appoints-dr-aarif-khakoo-as-chief-scientific-officer-and-head-of-research-and-development-and-dr-maria-mirotsou-as-vice-president-of-discovery-biology https://www.scribetx.com/news/scribe-therapeutics-biogen-collaborate-to-develop-crispr-based-genetic-medicines https://www.scribetx.com/news/scribe-therapeutics-closes-series-b-round-with-100m-to-target-gene-editing https://www.scribetx.com/news/scribe-therapeutics-co-founder-jennifer-doudna-receives-2020-nobel-prize-in-chemistry https://www.scribetx.com/news/scribe-therapeutics-continues-to-advance-the-development-of-its-crispr-platform-and-pipeline https://www.scribetx.com/news/scribe-therapeutics-converting-an-alameda-shipway-into-a-lab https://www.scribetx.com/news/scribe-therapeutics-emerges-with-20m-biogen-pact-to-clear-crispr-hurdles https://www.scribetx.com/news/scribe-therapeutics-expands-collaboration-with-biogen-to-second-target https://www.scribetx.com/news/scribe-therapeutics-expands-collaboration-with-sanofi-to-advance-in-vivo-genetic-medicines-for-sickle-cell-and-other-genomic-diseases https://www.scribetx.com/news/scribe-therapeutics-expands-in-vivo-collaboration-with-sanofi-to-second-target https://www.scribetx.com/news/scribe-therapeutics-gene-editing-tech-attracts-pharma-partners https://www.scribetx.com/news/scribe-therapeutics-highlights-latest-data-on-lp-a--lowering-therapy-and-novel-ai-platform-for-next-generation-crispr-based-therapeutics-at-two-premier-conferences https://www.scribetx.com/news/scribe-therapeutics-launches-a-platform-for-engineering-crispr-based-therapeutics https://www.scribetx.com/news/scribe-therapeutics-launches-to-explore-next-generation-crispr-technology https://www.scribetx.com/news/scribe-therapeutics-picks-cholesterol-lowering-as-first-in-vivo-gene-target https://www.scribetx.com/news/scribe-therapeutics-plans-to-test-cholesterol-lowering-epigenetic-editing-therapy https://www.scribetx.com/news/scribe-therapeutics-presents-data-demonstrating-highly-potent-gene-editing-in-vivo-including-saturated-editing-of-hepatocytes-in-nhps-by-an-engineered-xe-genome-editor-showcases-novel-epigenetic-editing-capabilities-at-2024-asgct-annual-meeting https://www.scribetx.com/news/scribe-therapeutics-presents-data-on-its-epigenetic-long-term-x-repressor-technology-at-the-2025-keystone-symposia-on-precision-genome-engineering-conference https://www.scribetx.com/news/scribe-therapeutics-presents-data-on-its-x-editing-technologies-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting https://www.scribetx.com/news/scribe-therapeutics-projected-to-enter-the-clinic-in-mid-2026-with-stx-1150-a-pcsk9-targeting-crispr-epigenetic-silencing-therapy-for-durable-ldl-c-reduction https://www.scribetx.com/news/scribe-therapeutics-raises-100m-series-b-financing-to-further-develop-crispr-by-design-platform-and-pipeline-of-breakthrough-genetic-medicines https://www.scribetx.com/news/scribe-therapeutics-reports-positive-preclinical-data-on-its-novel-crispr-technologies-at-the-2025-eas-congress-and-asgct-annual-meeting https://www.scribetx.com/news/scribe-therapeutics-reports-preclinical-data-validating-its-crispr-genome-editing-and-epigenome-modifying-technologies-for-addressing-cardiometabolic-disease-at-american-heart-association-aha-scientific-sessions-2024 https://www.scribetx.com/news/scribe-therapeutics-sets-out-to-write-crispr-gene-editings-next-chapter https://www.scribetx.com/news/scribe-therapeutics-snags-100m-for-engineered-crispr-tech-pipeline https://www.scribetx.com/news/scribe-therapeutics-to-collaborate-with-biogen-to-develop-crispr-based-genetic-medicines-for-neurological-diseases-including-als https://www.scribetx.com/news/scribe-therapeutics-to-demonstrate-scientific-and-corporate-leadership-at-upcoming-conferences https://www.scribetx.com/news/scribe-therapeutics-to-highlight-engineered-crispr-platform-advances-and-lead-cardiometabolic-pipeline-at-asgct-and-eas-congress-2026 https://www.scribetx.com/news/scribe-therapeutics-to-highlight-in-vivo-crispr-based-genome-editing-data-for-duchenne-muscular-dystrophy-at-asgct-2025-in-addition-to-joint-presentation-with-prevail-therapeutics-a-part-of-lillys-gene-therapy-division https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-four-upcoming-conferences https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-the-leerink-partners-global-biopharma-conference https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-upcoming-conferences https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-upcoming-conferences-2 https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-upcoming-goldman-sachs-the-new-guard-privates-leading-the-disruption-in-healthcare-investor-conference https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-upcoming-investor-conferences https://www.scribetx.com/news/scribe-therapeutics-to-participate-in-upcoming-investor-conferences-in-may-and-june https://www.scribetx.com/news/scribe-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference https://www.scribetx.com/news/scribe-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference https://www.scribetx.com/news/scribe-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference https://www.scribetx.com/news/scribe-therapeutics-to-present-on-advances-in-crispr-genome-and-epigenome-editing-at-the-2024-american-society-of-gene-cell-therapy-asgct-annual-meeting https://www.scribetx.com/news/scribe-therapeutics-to-present-preclinical-data-on-crispr-genome-and-epigenome-editing-technologies-at-american-heart-association-aha-scientific-sessions-2024 https://www.scribetx.com/news/scribe-therapeutics-to-unveil-latest-preclinical-data-on-proprietary-crispr-epigenetic-silencing-technology-for-ldl-c-lowering-at-the-2025-eas-congress https://www.scribetx.com/news/scribe-therapeutics-unveils-fully-integrated-platform-for-engineering-breakthrough-crispr-based-genetic-medicines https://www.scribetx.com/news/scribe-therapeutics-verifies-in-vivo-crispr-based-cardiometabolic-therapies https://www.scribetx.com/news/scribe-vertex-add-to-gene-therapys-advance-with-1b-deal-near-term-bla https://www.scribetx.com/news/scribes-crispr-tech-prevails-in-new-1-5b-biobucks-deal-with-lilly-unit https://www.scribetx.com/news/small-enzymes-giant-leaps-crisprs-next-generation-approach-to-genetic-diseases https://www.scribetx.com/news/starting-with-biogen-deal-in-als-scribe-planning-a-new-chapter-in-crispr-story https://www.scribetx.com/news/the-20-1-under-40-inside-the-next-generation-of-biotech-leaders https://www.scribetx.com/news/the-2024-pharmavoice-100 https://www.scribetx.com/news/the-age-of-crispr-engineering-the-future-of-genetic-medicine https://www.scribetx.com/news/the-latest-jennifer-doudna-startup-launches-with-a-biogen-partnership-and-eyes-on-big-targets-few-crispr-companies-have-chased https://www.scribetx.com/news/the-new-age-of-crispr https://www.scribetx.com/news/the-science-of-crispr-with-dr-benjamin-oakes https://www.scribetx.com/news/these-gene-editing-startups-are-aiming-to-solve-one-of-crisprs-biggest-problems-heres-how-they-could-upend-biotech-in-2022 https://www.scribetx.com/news/this-scientist-is-building-custom-gene-editing-tools----and-stands-to-make-billions https://www.scribetx.com/news/tiny-new-crispr-protein-could-make-human-gene-hacking-less-risky https://www.scribetx.com/news/top-five-privately-held-gene-editing-therapy-companies https://www.scribetx.com/news/top-life-sciences-startups-to-watch-in-2021 https://www.scribetx.com/news/towards-an-ai-driven-crispr-future https://www.scribetx.com/news/treating-high-cholesterol-could-become-a-one-and-done-treatment https://www.scribetx.com/news/u-s-innovation-strategy-needed-to-counter-chinas-rise-in-biotech https://www.scribetx.com/news/venture-investment-in-crispr-gene-editing-spurs-innovation-hunt-for-ip https://www.scribetx.com/news/watch-out-crispr-cas9-theres-a-new-and-smaller-gene-editor https://www.scribetx.com/news/with-rare-speed-gene-editing-emerges-as-biotechs-new-cutting-edge https://www.scribetx.com/news/women-ropestalk-conversation-with-svetlana-lucas-scribe-therapeutics https://www.scribetx.com/news/world-changing-ideas-awards-2021-health-finalists-and-honorable-mentions